Di seguito sono riportate le informazioni acquisite su ASTELLAS PHARMA INC, che non è ancora inclusa nel nostro perimetro di ricerca.

Per richiedere una valutazione di questa azienda e l'inserimento nel Ranking OpenCorporation o se hai dati ulteriori, diversi e più aggiornati di quanto pubblicato in questa scheda aziendale OpenCorporation, scrivi a info@opencorporation.org così che il nostro team possa tenerne conto.

Aggiornato il 31 marzo 2022

Descrizione attività
(disponibile solo in inglese)

Manufacture of pharmaceutical preparations (NACE2 2120)

This company is engaged in manufacturing, marketing and importing/exporting of pharmaceuticals and related products. The company was formed through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd in April 2005. It conducts business from its registered head office which is strategically located in Tokyo, Japan. The company contributes to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The company is targeting urology, immunology and inflammation, diabetes, central nervous system and pain, infectious diseases including viruses and cancer. Its major research laboratories in Japan are located in Tsukuba and Osaka and development bases are integrated in Tokyo. Clinical development is the primary focus of overseas operations, with a North American center in Illinois, and a European center in the Netherlands, with additional facilities in Germany. With one of the largest sales forces in Japan, it is further strengthening its marketing organization to consolidate its number one position in both quality and quantity in the domestic ethical drug market. It aims to establish competitive advantages in selected therapeutic areas, carrying a wide spectrum of products with sizable sales in each field. In Japan, mainstay products areas include: urology (Vesicare and Harnal), transplants and immunology (Prograf, Protopic and Intal), cardiovascular (Lipitor, Micardis, Dorner), gastrointestinal organs (Gaster), infection diseases (Fubguard, Targosid and Cefzon), and psychiatry (Myslee, Luvox and Seroquel). It is cementing its presence as an R&D driven global pharmaceutical company by further expanding its R&D, production, and marketing organizations in the U.S., the world's largest pharmaceutical market, as well as in major countries in Europe and Asia. In the US market, the company is achieving sustained growth in the transplants, cardiovascular, dermatology, infectious diseases and urology fields. In Europe, it also carries out R&D, manufacturing, and marketing. Its European headquarters in United Kingdom oversees the whole of Europe with its nineteen sales subsidiaries. In fast-growing Asian markets (China, Southeast Asia), it has already established marketing and production functions in China and marketing functions in Korea and Taiwan.

  • ASTELLAS PHARMA INC

  • Japan (JP)
  • Tipo di azienda: Corporate
  • Impresa controllante: N/D
  • Amministratore Delegato (CEO): Mr Yoshihiko Hatanaka
  • Compenso Amministratore Delegato: N/D
  • Sito web: www.astellas.com

Parametri finanziari

Numero di dipendenti

N/D
15,455
15,883
16,243

Fatturato 1

N/D
10
11
10

EBIT 1

N/D
1
2
2

EBITDA 1

N/D
3
3
3

1 numeri espressi in milioni

  • RepRisk indicator (ultimo mese):  18

Dialogo sociale

  • Transnational Corporate Agreement (TCA): N/D
  • Global Framework Agreement (GFA): N/D
  • Societas Europaea (SE): N/D
  • Bangladesh Accord: N/D

Comitati Aziendali Europei

  • CAE: N/D

Standard e certificazioni

Certificazione Global Reporting Initiative

  • Global Reporting Initiative standards: N/D
  • Global Reporting Initiative GRI G4: N/D

Altre dichiarative aziendali

Policy

  • Policy sulla formazione: N/D
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro dove opera l'azienda: N/D
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro lungo filiera: N/D
  • Policy sulla diversità: N/D

Dichiarazioni universali

Dichiarazioni e trattati riconosciuti dal paese in cui l'azienda ha la sede legale

  • Dichiarazione universale dei Diritti Umani:
  • Convenzione europea dei diritti dell'uomo (CEDU):
  • Carta dei Diritti Fondamentali dei Lavoratori CDFL (Carta di Strasburgo 1989):
  • Carta dei diritti fondamentali dell'Unione Europea CDF UE (Carta di Nizza 2000):
  • Trattato sul funzionamento dell'Unione europea TFUE:
  • Sede legale in un Paese OCSE:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Direttive applicate alle sedi nella UE 27

  • D. 80/987/EEC: N/D
  • D. 89/391/EEC: N/D
  • D. 98/59/EC: N/D
  • D. 2000/43/EC: N/D
  • D. 2000/78/EC: N/D
  • D. 2001/23/EC: N/D
  • D. 2001/86/EC del Consiglio: N/D
  • D. 2002/14/EC: N/D
  • D. 2002/73/EC: N/D
  • D. 2003/72/EC del Consiglio: N/D
  • D. 2005/56/EC del PE e del Consiglio: N/D
  • D. 2009/38/EC: N/D
  • D. 2004/25/EC: N/D
  • D. 2011/35/EU: N/D

Presenza nei principali ranking

  • Global 100 Most Sustainable Corporations:
  • Global CSR Rep Trak 100: N/D
  • BrandZ Top 100 Most Valuable US Brands: N/D
  • The Worlds Best Multinational Workplaces: N/D
  • The Gartner Supply Chain Top 25: N/D
  • The Worlds Most Innovative Companies: N/D
  • The Diversity Inc Top 50 Companies: N/D
  • Best Global Websites: N/D
  • Green Ranking Global Top 500: N/D
  • Green Ranking Global Top 100: N/D

Sindacati di riferimento